270 related articles for article (PubMed ID: 24810491)
21. Treatment eligibility and retention in clinical HIV care: A regression discontinuity study in South Africa.
Bor J; Fox MP; Rosen S; Venkataramani A; Tanser F; Pillay D; Bärnighausen T
PLoS Med; 2017 Nov; 14(11):e1002463. PubMed ID: 29182641
[TBL] [Abstract][Full Text] [Related]
22. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa.
Lawn SD; Myer L; Edwards D; Bekker LG; Wood R
AIDS; 2009 Aug; 23(13):1717-25. PubMed ID: 19461502
[TBL] [Abstract][Full Text] [Related]
23. Impact of antiretroviral therapy on the incidence of tuberculosis: the Brazilian experience, 1995-2001.
Miranda A; Morgan M; Jamal L; Laserson K; Barreira D; Silva G; Santos J; Wells C; Paine P; Garrett D
PLoS One; 2007 Sep; 2(9):e826. PubMed ID: 17786198
[TBL] [Abstract][Full Text] [Related]
24. The costs of providing antiretroviral therapy services to HIV-infected individuals presenting with advanced HIV disease at public health centres in Dar es Salaam, Tanzania: Findings from a randomised trial evaluating different health care strategies.
Kimaro GD; Mfinanga S; Simms V; Kivuyo S; Bottomley C; Hawkins N; Harrison TS; Jaffar S; Guinness L;
PLoS One; 2017; 12(2):e0171917. PubMed ID: 28234969
[TBL] [Abstract][Full Text] [Related]
25. What is the optimum time to start antiretroviral therapy in people with HIV and tuberculosis coinfection? A systematic review and meta-analysis.
Burke RM; Rickman HM; Singh V; Corbett EL; Ayles H; Jahn A; Hosseinipour MC; Wilkinson RJ; MacPherson P
J Int AIDS Soc; 2021 Jul; 24(7):e25772. PubMed ID: 34289243
[TBL] [Abstract][Full Text] [Related]
26. The Effect of Timing of Initiation of Antiretroviral Therapy on Loss to Follow-up in HIV-Tuberculosis Coinfected Patients in South Africa: An Open-Label, Randomized, Controlled Trial.
Yende-Zuma N; Naidoo K
J Acquir Immune Defic Syndr; 2016 Aug; 72(4):430-6. PubMed ID: 26990824
[TBL] [Abstract][Full Text] [Related]
27. The effect of interrupted anti-retroviral treatment on the reconstitution of memory and naive T cells during tuberculosis treatment in HIV patients with active pulmonary tuberculosis.
Nalukwago S; Lancioni CL; Oketcho JB; Canaday DHE; Boom WH; Ojok L; Mayanja-Kizza H
Afr Health Sci; 2017 Dec; 17(4):954-962. PubMed ID: 29937865
[TBL] [Abstract][Full Text] [Related]
28. Re-evaluating the health impact and cost-effectiveness of tuberculosis preventive treatment for modern HIV cohorts on antiretroviral therapy: a modelling analysis using data from Tanzania.
Zhu J; Lyatuu G; Sudfeld CR; Kiravu A; Sando D; Machumi L; Minde J; Chisonjela F; Cohen T; Menzies NA
Lancet Glob Health; 2022 Nov; 10(11):e1646-e1654. PubMed ID: 36240830
[TBL] [Abstract][Full Text] [Related]
29. Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters.
Writing Committee for the CASCADE Collaboration
Arch Intern Med; 2011 Sep; 171(17):1560-9. PubMed ID: 21949165
[TBL] [Abstract][Full Text] [Related]
30. HIV and TB co-infection in the ART era: CD4 count distributions and TB case fatality in Cape Town.
Kaplan R; Hermans S; Caldwell J; Jennings K; Bekker LG; Wood R
BMC Infect Dis; 2018 Jul; 18(1):356. PubMed ID: 30064368
[TBL] [Abstract][Full Text] [Related]
31. Short-course antiretroviral therapy in primary HIV infection.
; Fidler S; Porter K; Ewings F; Frater J; Ramjee G; Cooper D; Rees H; Fisher M; Schechter M; Kaleebu P; Tambussi G; Kinloch S; Miro JM; Kelleher A; McClure M; Kaye S; Gabriel M; Phillips R; Weber J; Babiker A
N Engl J Med; 2013 Jan; 368(3):207-17. PubMed ID: 23323897
[TBL] [Abstract][Full Text] [Related]
32. Fee for home delivery and monitoring of antiretroviral therapy for HIV infection compared with standard clinic-based services in South Africa: a randomised controlled trial.
Barnabas RV; Szpiro AA; Ntinga X; Mugambi ML; van Rooyen H; Bruce A; Joseph P; Ngubane T; Krows ML; Schaafsma TT; Zhao T; Tanser F; Baeten JM; Celum C; van Heerden A;
Lancet HIV; 2022 Dec; 9(12):e848-e856. PubMed ID: 36335976
[TBL] [Abstract][Full Text] [Related]
33. Effect on mortality and virological response of delaying antiretroviral therapy initiation in children receiving tuberculosis treatment.
Yotebieng M; Van Rie A; Moultrie H; Cole SR; Adimora A; Behets F; Meyers T
AIDS; 2010 Jun; 24(9):1341-9. PubMed ID: 20559039
[TBL] [Abstract][Full Text] [Related]
34. Financial incentives for reduced alcohol use and increased isoniazid adherence during tuberculosis preventive therapy among people with HIV in Uganda: an open-label, factorial randomised controlled trial.
Chamie G; Hahn JA; Kekibiina A; Emenyonu NI; Beesiga B; Marson K; Fatch R; Lodi S; Adong J; Thirumurthy H; McDonell MG; Gandhi M; Bryant K; Havlir DV; Kamya MR; Muyindike WR
Lancet Glob Health; 2023 Dec; 11(12):e1899-e1910. PubMed ID: 37973340
[TBL] [Abstract][Full Text] [Related]
35. Maternal health outcomes among HIV-infected breastfeeding women with high CD4 counts: results of a treatment strategy trial.
Hoffman RM; Angelidou KN; Brummel SS; Saidi F; Violari A; Dula D; Mave V; Fairlie L; Theron G; Kamateeka M; Chipato T; Chi BH; Stranix-Chibanda L; Nematadzira T; Moodley D; Bhattacharya D; Gupta A; Coletti A; McIntyre JA; Klingman KL; Chakhtoura N; Shapiro DE; Fowler MG; Currier JS;
HIV Clin Trials; 2018 Dec; 19(6):209-224. PubMed ID: 30890061
[TBL] [Abstract][Full Text] [Related]
36. High Rates of Drug-induced Liver Injury in People Living With HIV Coinfected With Tuberculosis (TB) Irrespective of Antiretroviral Therapy Timing During Antituberculosis Treatment: Results From the Starting Antiretroviral Therapy at Three Points in TB Trial.
Naidoo K; Hassan-Moosa R; Mlotshwa P; Yende-Zuma N; Govender D; Padayatchi N; Abdool-Karim SSS
Clin Infect Dis; 2020 Jun; 70(12):2675-2682. PubMed ID: 31622456
[TBL] [Abstract][Full Text] [Related]
37. Estimating the real-world effects of expanding antiretroviral treatment eligibility: Evidence from a regression discontinuity analysis in Zambia.
Mody A; Sikazwe I; Czaicki NL; Wa Mwanza M; Savory T; Sikombe K; Beres LK; Somwe P; Roy M; Pry JM; Padian N; Bolton-Moore C; Holmes CB; Geng EH
PLoS Med; 2018 Jun; 15(6):e1002574. PubMed ID: 29870531
[TBL] [Abstract][Full Text] [Related]
38. Community perspective on the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.
Geffen N; Aagaard P; Corbelli GM; Meulbroek M; Peavy D; Rappoport C; Schwarze S; Collins S;
HIV Med; 2015 Apr; 16 Suppl 1(0 1):10-3. PubMed ID: 25711318
[TBL] [Abstract][Full Text] [Related]
39. Socio-economic status and time trends associated with early ART initiation following primary HIV infection in Montreal, Canada: 1996 to 2015.
Mehraj V; Cox J; Lebouché B; Costiniuk C; Cao W; Li T; Ponte R; Thomas R; Szabo J; Baril JG; Trottier B; Côté P; LeBlanc R; Bruneau J; Tremblay C; Routy JP;
J Int AIDS Soc; 2018 Feb; 21(2):. PubMed ID: 29412520
[TBL] [Abstract][Full Text] [Related]
40. Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial.
Fidler S; Stöhr W; Pace M; Dorrell L; Lever A; Pett S; Kinloch-de Loes S; Fox J; Clarke A; Nelson M; Thornhill J; Khan M; Fun A; Bandara M; Kelly D; Kopycinski J; Hanke T; Yang H; Bennett R; Johnson M; Howell B; Barnard R; Wu G; Kaye S; Wills M; Babiker A; Frater J;
Lancet; 2020 Mar; 395(10227):888-898. PubMed ID: 32085823
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
